Multimodality prevention of contrast-induced acute kidney injury.
McCullough
Peter A
PA
William Beaumont Hospital, Royal Oak, Michigan 48073, USA. pmc975@yahoo.com
D000111:Acetylcysteine / Q000008:administration & dosage / Q000627:therapeutic use*; D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D016923:Cell Death; D015687:Cell Hypoxia; D032921:Consensus; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004847:Epithelial Cells / Q000187:drug effects / Q000473:pathology; D005440:Fluid Therapy; D006801:Humans; D007249:Inflammation; D007262:Infusions, Intravenous; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D015337:Multicenter Studies as Topic; D018384:Oxidative Stress; D017410:Practice Guidelines as Topic; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012079:Renal Circulation; D016896:Treatment Outcome
D000975:Antioxidants; D015415:Biomarkers; D003287:Contrast Media; D020011:Protective Agents; D003404:Creatinine; D001205:Ascorbic Acid; D000111:Acetylcysteine